Eligibility criteria for a clinical trial can contain dozens of variables, from lab results and diagnostic codes to comorbidities, medication histories, and other forms of medical data. For coordinators and investigators, that means poring through electronic health records (EHRs), verifying documentation, and making nuanced decisions about whether a patient fits the protocol before enrollment can begin.
Artificial intelligence (AI) doesn’t change the science or the criteria behind patient eligibility; it supports how clinical trial sites, sponsors, and CROs operationalize those rules. AI helps identify and match patients who are more likely to qualify, reduces time spent on ineligible candidates, and enables better alignment between protocol design and real-world clinical practice while protecting patient outcomes.
Here’s how that process unfolds and where AI fits in.
Eligibility criteria are a multi-layered clinical framework used to protect clinical trial patients and guide protocol compliance. These layers ensure that patient data is applied correctly to determine fit, safety, and potential benefit.
Each layer is critical, and missing just one detail can mean enrolling the wrong patient. This can:
That’s why getting eligibility right the first time around is a must. It’s also why AI, when applied thoughtfully, can be such a powerful support system for busy clinical research teams.
Artificial intelligence doesn’t define patient eligibility criteria, but it can make applying those criteria significantly easier and faster for coordinators and investigators.
Here’s how AI-powered tools can support the process from start to finish:
AI can scan structured fields in the EHR (such as diagnosis codes, lab values, medications, and demographics) to quickly assess whether a patient appears to meet key inclusion and exclusion criteria. This helps filter out clearly ineligible patients early in the process.
Many critical data points live in unstructured notes, like radiology reports or clinician narratives. Natural Language Processing (NLP) models can extract mentions of qualifying terms (e.g., “Stage 3 CKD” or “history of myocardial infarction”) that may not be coded but are relevant to the clinical trial.
Once eligibility criteria are programmed into an AI system, it can continuously monitor EHR systems to flag patients who newly qualify based on lab results, diagnoses, or medication changes. This enables just-in-time patient recruitment.
Advanced machine learning models can assign an eligibility likelihood score based on the completeness and alignment of a patient’s profile. From there, sites can then prioritize outreach to the most promising candidates, saving time and resources in clinical trial recruitment.
AI can also flag potential exclusion risks that might be overlooked during manual review, particularly in complex protocols. Examples include prohibited medications or overlapping clinical trial participation.
By supporting eligibility assessments in these ways, AI brings tangible, measurable benefits to the patient selection process:
AI is helpful across all clinical trials, but its value is magnified in certain scenarios:
For acute infections like RSV, influenza, or COVID-19, enrollment windows are short. AI can monitor EHRs and lab feeds in real time to flag newly diagnosed patients who meet eligibility, allowing site staff to act quickly before the window closes.
With narrow criteria and low-prevalence populations, rare disease trials require finding the right patient out of thousands. AI can efficiently scan large datasets to identify subtle diagnostic patterns, genetic markers, or treatment histories that indicate eligibility.
These studies often require enrolling healthy volunteers who meet strict baseline criteria, including no prior exposure, normal lab values, and a clean medical history. AI can help pre-screen large patient databases to rule out common disqualifiers and surface high-probability candidates faster.
Even with AI at your side, clinical judgment can’t be outsourced.
There’s still a need to:
And before any of that can happen, eligibility criteria must be defined. AI can help scale the process, but it can’t determine what’s clinically appropriate, ethically sound, or operationally realistic.
At Remington-Davis, we take a consultative role with sponsors and CROs, helping shape eligibility criteria that are both scientifically rigorous and feasible in the real world. Once defined, we use technology to support our efforts — but always with a human lens.
For example, we use EHR-based pre-screening to identify high-probability candidates faster; then coordinators validate eligibility manually and document criteria in eSource/eReg for clean audit trails. Throughout the study, CTMS-based workflows and automated reminders support visit adherence and reduce preventable screen failures and discontinuations.
The art of patient selection lives in that balance. Technology helps us move faster. Our experience helps us move smarter. And our people make sure patients feel understood, supported, and confident.
If you're looking for a partner to manage your next clinical trial, let's talk.
Patient selection refers to determining whether an individual is eligible to participate in a trial based on inclusion/exclusion criteria. Patient recruitment is the broader process of attracting and engaging potential participants — through advertising, outreach, referrals, and more — before they are screened for eligibility.
By helping sites enroll patients who more precisely match a study’s inclusion and exclusion criteria, AI improves the consistency and reliability of trial data. This leads to cleaner endpoints, fewer outliers, and more meaningful results. AI also reduces the likelihood of enrolling borderline or ineligible patients who may drop out or require early discontinuation. In short, better patient matching from the start improves patient retention and chances of producing valid, actionable trial results.
AI can help predict recruitment timelines by analyzing population-level data, identify high-performing sites based on historical trial performance, and even flag potential protocol deviations before they occur. Additionally, AI plays a growing role in remote monitoring and data cleaning, streamlining data management and reducing site burden.
One of the main challenges is ensuring that AI tools align with real-world clinical workflows. Many platforms aren’t fully integrated with EHR systems or require data that isn’t consistently structured across records. Another challenge is ensuring that AI respects regulatory and ethical standards.
Yes, indirectly. By ensuring patients meet eligibility criteria related to pre-existing conditions, lab values, or contraindications, AI reduces the risk of enrolling individuals who may be harmed by study participation. It also helps catch exclusion flags early in the process, before an ineligible participant progresses through screening.